Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform ...

-- Viral Vector Facility Further Strengthens Vertical Integration of Kite’s Global CAR T-cell Therapy Manufacturing Network, Supports Growing Demand of Company’s Blood Cancer Treatments -- -- Kite is ...

The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing of 413 viral vector deals announced ...